Guangdong True Health Medical Technology

Guangdong True Health Medical Technology (Ticker: 2697 HK) develops and commercializes surgical robots and related equipment for minimally invasive procedures. Founded in 2018, the company’s main product is a surgical robot that helps doctors guide needles through the skin to areas such as the lung or abdomen for diagnosis or treatment. Several models of its puncture surgical robot have NMPA Class III registrations. The offering consists entirely of primary shares.

The scheduled listing date on Hong Kong Stock Exchange was June 30, 2026. The proposed offering comprises 3,560,000 shares at an indicative price range of HKD 119.30–135.60 per share. At the indicative range midpoint, the base offering would represent HKD 453.72 million, approximately $57.81 million in gross proceeds, excluding any unexercised over-allotment.

ABCI Capital, CMBC Securities, CICC, and DBS Asia Capital are joint managers.